Johnson & Johnson vs Merck &
Johnson & Johnson is the larger business, with $94.19bn of revenue in fiscal 2025 against $65.01bn for Merck & (1.4 times as much). Johnson & Johnson grew faster (6.0% against 1.3%). Johnson & Johnson kept more of each dollar of sales as profit: a net margin of 28.5% against 28.1%. Johnson & Johnson carries less debt relative to equity (61.2% against 93.8%).
| Latest fiscal year | Johnson & JohnsonJNJ, 2025 | Merck &MRK, 2025 |
|---|---|---|
| Revenue | $94.19bn | $65.01bn |
| Revenue growth | 6.0% | 1.3% |
| Net income | $26.80bn | $18.25bn |
| Operating margin | — | — |
| Net margin | 28.5% | 28.1% |
| Return on equity | 35.0% | 36.9% |
| Free cash flow | $19.70bn | $12.36bn |
| Cash | $19.71bn | $14.56bn |
| Total debt | $49.93bn | $49.34bn |
| Debt to equity | 61.2% | 93.8% |
| Dividend per share | $5.14 | $3.28 |
| Dividend yield | 1.9% | 2.3% |
| Share buybacks | $5.95bn | $5.08bn |
| Employees | 138,200 | — |
| Market value | $651.18bn | $354.85bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 92 (Strong) | 79 (Strong) |
| Insider trades, 12 months | 1 buys, 36 sales | 0 buys, 35 sales |